The outlook of companies tied to flagship drugs like Viagra presents a complex investment picture. While the initial boom of copyright, fueled by Viagra's unprecedented popularity, generated substantial returns, the patent expiration in key territories has introduced considerable uncertainty . Investors are now assessing the consequences of lower-c